Rencontrez-nous à…
Toute l’actualité d’OTR3
Lungs/Poumons | Media Publications
Laurie Perdigon (1) , Manon Barthe (1) , Hanan Osman-Ponchet (1) , Agnes Choppin (2) , Franck Chiappini (2) Human precision-cut lung slices (hPCLS) are a promising ex vivo model for respiratory research. These thin, precisely-cut tissues, obtained from fresh lungs using a vibrating microtome, retain the native 3D architecture [...]
Lungs/Poumons | Media Publications
Manon Barthe (1) , Laurie Perdigon (1) , Hanan Osman-Ponchet (1) , Agnès Choppin (2) , Franck Chiapini (2) Pulmonary fibrosis is a progressive, restrictive lung disease characterized by scarring and stiffening of lung tissue, ultimately leading to respiratory failure. This condition is driven by the excessive proliferation and migration [...]
News
OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.
News
OTR3 appoints new management teams as the company planned to launch a second generation of RGTA® products.
Cacipliq 20
Cacipliq 20® - Ischemic wound First Clinical Pilot Study on critical ischemic leg ulcers with Matrix Therapy ReGeneraTing Agent (RGTA ® ) technology P. DESGRANGES, T. LOUISSAINT, E. ALLAIRE, B. GODEAU, K. KICHENIN, J.- P. BECQUEMIN, D. BARRITAULT Patients with non-healing leg ulcers due to severe limb ischemia and [...]
Cacipliq 20
Cacipliq 20® - Chronic wound Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study Groah SL, Libin A, Spungen M, Nguyen KL, Woods E, Nabili M, Ramella-Roman J, Barritault D. The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan [...]
